



Editorial Editorial for the Special Issue "Acute and Chronic Pancreatitis, Pancreatic Malignancies"

Antanas Gulbinas ^{1,2}, Povilas Ignatavicius ¹, and Zilvinas Dambrauskas ^{1,2,*}

- ¹ Department of Surgery, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania; antanas.gulbinas@lsmuni.lt (A.G.); povilas.ignatavicius@lsmuni.lt (P.I.)
- ² Institute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania
- * Correspondence: zilvinas.dambrauskas@gmail.com

Pancreatic diseases, especially acute pancreatitis and pancreatic cancer, are associated with high rates of complications, difficult treatment that may not always be effective, and high mortality in complex cases. Therefore, this Special Issue aims to discuss the current trends in the diagnosis and management of pancreatic diseases, and share the most recent findings from genetic, molecular, and clinical studies in pancreatology, including acute pancreatitis, cystic lesions, and pancreatic cancer. We are proud to introduce several papers presenting cutting-edge research focusing on the molecular mechanisms of pancreatic diseases, and novel approaches to the diagnosis, prognostication, and treatment of acute pancreatitis and pancreatic malignancies.

Acute pancreatitis (AP) is an insidious, potentially fatal disease affecting not only the pancreas and surrounding tissues, but also other internal organs and organ systems. While most patients with AP have a mild course and the disease is self-limiting, about 20% of AP patients progress to severe disease [1]. When choosing treatment options for acute pancreatitis, several challenges and disagreements arise. If severe acute pancreatitis (SAP) with organ failure develops, patients often need to be transferred to the intensive care unit. Therefore, it is essential to recognize severe disease in the early phase of AP and select patients who would benefit from early interventions [1].

Pancreatic acinar cell injury triggers the release of pro-inflammatory cytokines and chemokines. Subsequently, this initiates an acute inflammatory response, in a manner that is similar to the molecular/signaling events observed in sepsis. The secretion patterns of pro- and anti-inflammatory cytokines have been analyzed in numerous clinical and experimental studies. Most of them show that the deregulation of the cellular immune system is a key event leading to severe AP [2]. However, the study by Zhou R et al. showed that the trend of cytokine expression in rats with SAP was not consistent with the disease progression, and the dominant cytokine–cytokine receptor interactions were always highly expressed at various time points over the course of SAP [3].

Several methods for estimating the severity of AP are widely used today and include APACHE II, the Imrie and Ranson scores, the CT scoring system, and measurement of C-reactive protein and a number of laboratory markers [4–10]. The current Special Issue includes a study by Sui Y et al. that confirms the possibility of using Fibrinogen-like Protein 1 as a predictive marker for the stratification of AP and its infectious complications [11]. The Controlling Nutritional Status (CONUT) score and prognostic nutritional index (PNI) were proven to be useful prognostic markers not only for predicting nutritional status but also for estimating the severity and outcomes of AP [12].

Early and accurate prediction of disease severity is one of the first steps when choosing the optimal treatment [13]. Identification of the location and extent of pancreatic necrosis could predict specific complications, such as fluid collections [14]. The study by Dekeryte et al. concluded that in patients with pancreatic necrosis exceeding 50%, the clinical



Citation: Gulbinas, A.; Ignatavicius, P.; Dambrauskas, Z. Editorial for the Special Issue "Acute and Chronic Pancreatitis, Pancreatic Malignancies". *Medicina* 2023, 59, 984. https://doi.org/10.3390 /medicina59050984

Received: 9 May 2023 Accepted: 16 May 2023 Published: 19 May 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). course and outcomes were worse. These patients most often developed severe AP, spent more time in the hospital and ICU, and more often needed surgical interventions with more complex treatment. Therefore, timely diagnosis of pancreatic necrosis and evaluation of its volume and extent are highly important in the management of patients with acute necrotizing pancreatitis [15]. Accurate radiological evaluation is of utmost importance for choosing the treatment options when walled-off pancreatic necrosis (WON) is present. This type of necrosis can be intra-pancreatic, peri-pancreatic, or both. Several studies have reported that the following minimally invasive approaches can achieve better outcomes: endoscopic transluminal drainage (ETD) with or without necrosectomy, laparoscopic or retroperitoneal surgical approach, and radiology-guided percutaneous approach followed by necrosectomy [16–18]. However, the study by Pattarapuntakul T et al. highlights the advantages of endoscopic transluminal drainage (ETD) with or without necrosectomy [19].

Intraductal papillary mucinous neoplasm (IPMN) is a potentially premalignant lesion of the pancreas, and patients diagnosed with main-duct and mixed-type IPMN, in particular, are often scheduled for pancreatic resection. Analysis of the 5-year experience of the Department of Digestive Tract Surgery of the Medical University of Silesia, Katowice, Poland, revealed that IPMN was the most frequent resected pancreatic cystic tumor (PCT). In patients with PCTs, due to substantial postoperative morbidity, adequate patient selection, considering both the surgical risk and the long-term risk of malignant transformation, is very important. The analysis showed that the distribution of different types of PCTs in a large Eastern European center was similar to that in North American and Western European populations, but differed from that in Eastern (Indian and Chinese) populations [20].

This Special Issue incorporates three review papers on pancreatic tumors stating that lifestyle seems to be a major contributor to the development of pancreatic cancer. Special attention should be given to individuals with a vicious cluster consisting of metabolic syndrome, tobacco smoking, and alcohol consumption [21]. Moreover, the multidisciplinary approach of establishing pancreatic cancer resectability [22] and prognostication of pancreatic fistulas following resection with regard to early postoperative hypophosphatemia is discussed [23].

Unresectable pancreatic cancer results in extremely low rates of survival; therefore, management of the leading complications such as biliary obstruction should be carried out under a minimally invasive but effective approach. Currently, the standard approach in those cases is endoscopic stenting via endoscopic retrograde cholangiopancreatography (ERCP). EUS-guided choledochoduodenostomy is an alternative option for palliative management of malignant distal biliary obstruction [24].

In summary, this Special Issue presents the latest evidence concerning the mechanisms, diagnosis, and management of pancreatic diseases. The development of novel strategies in the management of pancreatic diseases is increasingly moving towards the personalized medicine direction. This is the only way of future management of these challenging conditions.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Hong, W.; Pan, J.; Goyal, H.; Zippi, M. Editorial: Acute pancreatitis infection: Epidemiology, prevention, clinical characteristics, treatment, and prediction. *Front. Cell Infect. Microbiol.* **2023**, *13*, 1175195. [CrossRef] [PubMed]
- Dambrauskas, Z.; Giese, N.; Gulbinas, A.; Giese, T.; Berberat, P.O.; Pundzius, J.; Barauskas, G.; Friess, H. Different profiles of cytokine expression during mild and severe acute pancreatitis. *World J. Gastroenterol.* 2010, 16, 1845–1853. [CrossRef] [PubMed]
- 3. Zhou, R.; Bu, W.; Fan, Y.; Du, Z.; Zhang, J.; Zhang, S.; Sun, J.; Li, Z.; Li, J. Dynamic Changes in Serum Cytokine Profile in Rats with Severe Acute Pancreatitis. *Medicina* 2023, *59*, 321. [CrossRef]
- Knaus, W.A.; Draper, E.A.; Wagner, D.P.; Zimmerman, J.E. Prognosis in acute organ-system failure. Ann. Surg. 1985, 202, 685–693. [CrossRef]
- Pezzilli, R.; Billi, P.; Miniero, R.; Fiocchi, M.; Cappelletti, O.; Morselli-Labate, A.M.; Barakat, B.; Sprovieri, G.; Miglioli, M. Serum interleukin-6, interleukin-8, and beta 2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein. *Dig. Dis. Sci.* 1995, 40, 2341–2348. [CrossRef] [PubMed]

- 6. Ranson, J.H. Etiological and prognostic factors in human acute pancreatitis: A review. Am. J. Gastroenterol. 1982, 77, 633–638.
- 7. Ranson, J.H.; Balthazar, E.; Caccavale, R.; Cooper, M. Computed tomography and the prediction of pancreatic abscess in acute pancreatitis. *Ann. Surg.* **1985**, *201*, 656–665. [CrossRef]
- Wilson, C.; Heads, A.; Shenkin, A.; Imrie, C.W. C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br. J. Surg. 1989, 76, 177–181. [CrossRef]
- 9. Wilson, C.; Heath, D.I.; Imrie, C.W. Prediction of outcome in acute pancreatitis: A comparative study of APACHE II, clinical assessment and multiple factor scoring systems. *Br. J. Surg.* **1990**, *77*, 1260–1264. [CrossRef]
- 10. Dambrauskas, Z.; Pundzius, J.; Barauskas, G. Predicting development of infected necrosis in acute necrotizing pancreatitis. *Medicina* **2006**, *42*, 441–449.
- 11. Sui, Y.; Zhao, Z.; Zhang, Y.; Zhang, T.; Li, G.; Liu, L.; Tan, H.; Sun, B.; Li, L. Fibrinogen-like Protein 1 as a Predictive Marker for the Incidence of Severe Acute Pancreatitis and Infectious Pancreatic Necrosis. *Medicina* **2022**, *58*, 1753. [CrossRef] [PubMed]
- Akkuzu, M.Z.; Altıntaş, E.; Yaraş, S.; Sezgin, O.; Ateş, F.; Üçbilek, E.; Özdoğan, O. Controlling Nutritional Status (CONUT) Score and Prognostic Nutritional Index (PNI) Are Good Candidates for Prognostic Markers for Acute Pancreatitis. *Medicina* 2023, 59, 70. [CrossRef] [PubMed]
- 13. Besselink, M.; van Santvoort, H.; Freeman, M.; Gardner, T.; Mayerle, J.; Vege, S.S.; Werner, J.; Banks, P.; McKay, C.; Fernandez-del Castillo, C.; et al. IAP/APA Evidence-Based Guidelines for the Management of Acute Pancreatitis. *Pancreatology* **2013**, *13*, E1–E15.
- 14. Verdonk, R.C.; Sternby, H.; Dimova, A.; Ignatavicius, P.; Koiva, P.; Penttila, A.K.; Ilzarbe, L.; Regner, S.; Rosendahl, J.; Bollen, T.L. Short Article: Presence, Extent and Location of Pancreatic Necrosis Are Independent of Aetiology in Acute Pancreatitis. *Eur. J. Gastroenterol. Hepatol.* **2018**, *30*, 342. [CrossRef]
- 15. Dekeryte, I.; Zviniene, K.; Bieliuniene, E.; Dambrauskas, Z.; Ignatavicius, P. Volume, but Not the Location of Necrosis, Is Associated with Worse Outcomes in Acute Pancreatitis: A Prospective Study. *Medicina* **2022**, *58*, 645. [CrossRef] [PubMed]
- Bang, J.Y.; Arnoletti, J.Y.; Holt, J.P.; Sutton, B.; Hasan, M.K.; Navaneethan, U.; Feranec, N.; Wilcox, C.M.; Tharian, B.; Hawes, R.H.; et al. An endoscopic transluminal approach, compared with minimally invasive surgery, reduces complications and costs for patients with necrotizing pancreatitis. *Gastroenterology* 2019, 156, 1027.e3–1040.e3. [CrossRef] [PubMed]
- Zhang, Y.; Zhang, S.Y.; Gao, S.L.; Liang, Z.Y.; Yu, W.Q.; Liang, T.B. Successful resolution of gastric outlet obstruction caused by pancreatic pseudocyst or walled-off necrosis after acute pancreatitis: The role of percutaneous catheter drainage. *Pancreas* 2015, 44, 1290–1295. [CrossRef]
- Moyer, M.T.; Walsh, L.T.; Manzo, C.E.; Loloi, J.; Burdette, A.; Mathew, A. Percutaneous debridement and washout of walled-off abdominal abscess and necrosis by the use of flexible endoscopy: An attractive clinical option when transluminal approaches are unsafe or not possible. *VideoGIE* 2019, *4*, 389–393. [CrossRef]
- Pattarapuntakul, T.; Charoenrit, T.; Wong, T.; Netinatsunton, N.; Ovartlarnporn, B.; Yaowmaneerat, T.; Tubtawee, T.; Boonsri, P.; Sripongpun, P. Clinical Outcomes of the Endoscopic Step-Up Approach with or without Radiology-Guided Percutaneous Drainage for Symptomatic Walled-Off Pancreatic Necrosis. *Medicina* 2023, 59, 569. [CrossRef]
- Jabłońska, B.; Gudz, A.; Hinborch, T.; Bujała, B.; Biskup, K.; Mrowiec, S. Pancreatic Cystic Tumors: A Single-Center Observational Study. *Medicina* 2023, 59, 241. [CrossRef]
- Olakowski, M.; Bułdak, Ł. Modifiable and Non-Modifiable Risk Factors for the Development of Non-Hereditary Pancreatic Cancer. *Medicina* 2022, 58, 978. [CrossRef] [PubMed]
- Gulla, A.; Hashimoto, D.; Wagner, D.; Damaseviciute, R.; Strupas, K.; Satoi, S. Interdisciplinary Approach of Establishing PDAC Resectability: Biochemical, Radiological and NAT Regimen Prognostic Factors—Literature Review. *Medicina* 2022, *58*, 756. [CrossRef] [PubMed]
- 23. Grikyte, I.; Ignatavicius, P. Postoperative Hypophosphatemia as a Prognostic Factor for Postoperative Pancreatic Fistula: A Systematic Review. *Medicina* 2023, *59*, 274. [CrossRef] [PubMed]
- 24. Hristov, B.; Radev, D.; Uchikov, P.; Kostov, G.; Doykov, M.; Valova, S.; Tilkiyan, E. Clinical Outcomes of EUS-Guided Choledochoduodenostomy for Biliary Drainage in Unresectable Pancreatic Cancer: A Case Series. *Medicina* 2023, 59, 351. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.